Management
Team

Mr. Pierre Laurin is a senior executive with more than 35 years of experience in the pharmaceutical and biotechnology industry. He founded Prometic Life Sciences Inc. in 1994 and took the company public on the Toronto Stock Exchange in 1998. He served as President and Chief Executive Officer of the Corporation since its inception until December 2018 during which period he raised close to $1 billion in equity, debt financing and multinational funding. Mr. Laurin's corporate development achievements include the successful closing of multiple licensing agreements and partnering agreements with multinationals, including two strategic agreements with the American Red Cross, which led to commercial applications and blood derived therapeutics. Mr. Laurin's prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi) where he played a pivotal role in the development and commercial success of Cardizem® in Canada and in the UK.

He is currently a board member of Innodem Neurosciences Inc., Innovon Pharmaceuticals Inc. and Invhealth Capital Inc. Mr. Laurin holds a Bachelor degree in Pharmacy and an MSc degree in Pharmaceutical Sciences from the University of Montreal.

Mr. Mainville has an accomplished history of financial and operational leadership successes within the life science industry. In an executive management career that spans more than 20 years, he has led or been integrally involved in four go-public transactions, completed more than 20 public financings, and managed more than 50 licensing, merger and acquisition, and sale transactions.

Mr. Mainville also serves as Senior Vice President and CFO for Valeo Pharma. His earlier experience includes senior management and financial roles with various life science companies, including Acerus Pharma, Cardiome Pharma, Neopharm Labs and LAB Research Inc. Prior to launching his career in the life science industry, Mr. Mainville was a Partner at KPMG LLP. Mr. Mainville has also served as Vice-Chairman of BIOTECanada and holds an MBA from McGill University.

Mr. Allard is a lawyer and Member of the Quebec Bar since 1996. In addition to his position with Valeo Pharma, Mr. Allard is Vice-President, Legal Affairs and Corporate Secretary for Manitex Capital Inc. and ChitogenX Inc., two affiliates of Valeo Pharma, since April 2016. From 2007 to 2016, he was Partner and Counsel at Dentons, a multinational law firm where he specialized in corporate finance, securities, and mergers and acquisitions. Throughout his career, he has been counsel to several publicly-listed companies on various matters.

Mr. Allard holds a Bachelor's degree in Business Administration (B.A.A), a Certificate in Law and a Bachelor's degree in Law (LL.B.) from Laval University (Quebec City).

Dr. Jonathan Sackier is a physician entrepreneur with diverse contributions to the health care industry including a large surgical practice, academic work, and work in the healthcare industry as a serial entrepreneur having licensed several of his own surgical inventions. He serves, among other assignments, as SVP Medical Affairs for ChitogenX. He was a Founding Partner and Director of Computer Motion, which built the world's first surgical robot (AESOP) which then eventually merged into Intuitive Surgical to become the largest surgical robotics company in the world. Dr. Sackier has also served as a Visiting Professor at Oxford University and as a Professor at George Washington University.

Dr. Sackier holds an Mb,ChB, Medicine from Liverpool University and completed fellowships with both the Royal College of Surgeons and the American College of Surgeons